FLAIR MRI的参数反应映射可早期提示胶质母细胞瘤进展风险
研究对52例胶质母细胞瘤患者的纵向标准化FLAIR图像进行体素级参数反应映射(PRM),分析PRMrFLAIR+、PRMrFLAIR-和PRMrFLAIR0的体积分数。在26例按RANO标准为疾病稳定或部分缓解的亚组中,PRMrFLAIR+在第10至20周及连续评估中可分层无进展生存和总生存,而FLAIR体积变化无预测价值。结论认为PRMrFLAIR可能提供胶质母细胞瘤疾病进展的早期生物标志物。
要点
- PRMrFLAIR+在第10周可分层PFS(p<0.01)和OS(p<0.001)。
- 在26例RANO稳定或部分缓解者中,PRMrFLAIR+可分层第10至20周进展(PFS p<0.05;OS p=0.01),FLAIR体积变化无预测价值。
- PRMrFLAIR+超过10%连续评估可在5.6个月分层PFA(p<0.0001),RANO标准至15.4个月才分层(p<0.0001)。
关键影像表现/征象
- PRM将rFLAIR信号分为增加(PRMrFLAIR+)、降低(PRMrFLAIR-)或不变(PRMrFLAIR0)的体素体积分数。
- 基于第10周RANO标准、FLAIR高信号体积相对变化和PRMrFLAIR+均可分层PFS和OS。
诊断标准与关键数值
- 第10周RANO标准分层PFS(p<0.0001)和OS(p<0.0001)。
- 第10周FLAIR高信号体积相对变化分层PFS(p=0.0011)和OS(p<0.0001)。
- 第10周PRMrFLAIR+分层PFS(p<0.01)和OS(p<0.001)。
- 第10至20周PRMrFLAIR+分层应答患者的进展(PFS p<0.05;OS p=0.01),而FLAIR体积测量变化无预测价值。
- 连续评估中PRMrFLAIR+超过10%在5.6个月分层PFA(p<0.0001),RANO标准至15.4个月才分层(p<0.0001)。
临床应用与阅片要点
- 原文结论认为PRMrFLAIR可能提供胶质母细胞瘤疾病进展的早期生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Glioblastoma image evaluation utilizes Magnetic Resonance Imaging contrast-enhanced, T1-weighted, and noncontrast T2-weighted fluid-attenuated inversion recovery (FLAIR) acquisitions. Disease progression assessment relies on changes in tumor diameter, which correlate poorly with survival. To improve treatment monitoring in glioblastoma, we investigated serial voxel-wise comparison of anatomically-aligned FLAIR signal as an early predictor of GBM progression.
MATERIALS AND METHODS: We analyzed longitudinal normalized FLAIR images (rFLAIR) from 52 subjects using voxel-wise Parametric Response Mapping (PRM) to monitor volume fractions of increased (PRMrFLAIR+), decreased (PRMrFLAIR-), or unchanged (PRMrFLAIR0) rFLAIR intensity. We determined response by rFLAIR between pretreatment and 10 weeks posttreatment. Risk of disease progression in a subset of subjects (N = 26) with stable disease or partial response as defined by Response Assessment in Neuro-Oncology (RANO) criteria was assessed by PRMrFLAIR between weeks 10 and 20 and continuously until the PRMrFLAIR+ exceeded a defined threshold. RANO defined criteria were compared with PRM-derived outcomes for tumor progression detection.
RESULTS: Patient stratification for progression-free survival (PFS) and overall survival (OS) was achieved at week 10 using RANO criteria (PFS: p <0.0001; OS: p <0.0001), relative change in FLAIR-hyperintense volume (PFS: p = 0.0011; OS: p <0.0001), and PRMrFLAIR+ (PFS: p <0.01; OS: p <0.001). PRMrFLAIR+ also stratified responding patients' progression between weeks 10 and 20 (PFS: p <0.05; OS: p = 0.01) while changes in FLAIR-volume measurements were not predictive. As a continuous evaluation, PRMrFLAIR+ exceeding 10% stratified patients for PFA after 5.6 months (p<0.0001), while RANO criteria did not stratify patients until 15.4 months (p <0.0001).
CONCLUSION: PRMrFLAIR may provide an early biomarker of disease progression in glioblastoma.
引用
- Hoff BA, Lemasson B, Chenevert TL, et al. Parametric Response Mapping of FLAIR MRI Provides an Early Indication of Progression Risk in Glioblastoma. Acad Radiol. 2020. PMID: 32928633. doi:10.1016/j.acra.2020.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。